Agenus Inc news

   Watch this stock
Showing stories 1 - 10 of about 100   

Articles published

AGEN 7.26 +0.35 (5.07%)
price chart
Agenus Inc. (NASDAQ:AGEN) Analyst Rating Update
Wall Street analysts polled by Zacks Research have given Agenus Inc. (NASDAQ:AGEN) a rating of 1 on a consensus basis. Using a simplified scale where 1 is a Strong Buy and 5 a Strong Sell, this is the average number of the 3 brokerages surveyed.
Agenus Inc. (NASDAQ:AGEN) Price Target Update  Insider Trading Report
Why It's Not Too Late to Buy Agenus, Inc. Stock
Shares of clinical-stage biopharma Agenus (NASDAQ:AGEN) have been on fire since the company acquired 4-Antibody in February 2014, allowing it to greatly expand its activities in the burgeoning field of immuno-oncology.
Why Agenus Inc. Shares Are Soaring Today
What: Shares in Agenus (NASDAQ:AGEN) shot higher by more than 10% today after the company reported first quarter financial results yesterday and compelling phase 3 data for its malaria vaccine today.
Agenus Inc. (NASDAQ:AGEN) reported a loss in the first quarter  Inside Trade
Agenus Inc (NASDAQ:AGEN) on Watch List
[ZACKS] Agenus Inc (NASDAQ:AGEN)(TREND ANALYSIS) shares were up 4% on the extension of its existing collaboration and license agreement with Merck MRK for the discovery and development of therapeutic antibodies to Merck's proprietary immune ...
Agenus Inc. Price Target Update
Agenus Inc. (NASDAQ:AGEN) shares are expected to touch $13 in the short term. This short term price target has been shared by 3 analysts.
Active Biotech Stock News - Oncothyreon Inc (USA) (NASDAQ:ONTY), Agenus Inc ...  Wall Street Observer
Agenus Receives $12.50 Average Target Price from Analysts (NASDAQ:AGEN)  sleekmoney
Zacks Short Term Rating on Agenus Inc. (NASDAQ:AGEN)
As many as 4 brokerage firms have rated Agenus Inc. (NASDAQ:AGEN) at 1. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term.
Shares of Agenus Inc. (NASDAQ:AGEN) Drops by -3.16%
Agenus Inc. (NASDAQ:AGEN) has lost 3.16% during the past week and dropped 17.76% in the last 4 weeks. The shares have outperformed the S&P 500 by 2.76% in the past week but underperformed the index by 13.22% in the last 4 weeks.
Agenus Receives $12.50 Average PT from Brokerages (NASDAQ:AGEN)  Financial Wisdom Works
Agenus Inc. Short Interest Update
Agenus Inc. (NASDAQ:AGEN) ensharesed a rise of 0.8% or 78,670 shares in the short positions. The number escalated from 9,472,242 on July 31,2015 to 9,550,912 on August 14,2015.
Why Agenus Inc. Shares Surged Higher In Early Trading Today
What: Amid an industrywide sell-off, shares in the biotech company Agenus (NASDAQ:AGEN) jumped by 10% on the open today after the company announced that positive data from a key trial was reported in the New England Journal of Medicine.
Agenus (AGEN) Stock | Why Declines Won't Last  CNA Finance (press release)
Jim Cramer on Agenus (AGEN) Stock: 'I Still Like It'  TheStreet.com
Agenus Inc (NASDAQ:AGEN) Initiated with a Buy at H.C. Wainwright
Out of 5 analysts covering Agenus Inc, 6 rate it a Buy, 1 indicate a Hold while 0 suggest a Sell. The highest target is $14 and the lowest is $9 according to Thomson/First Call.
Why Agenus (AGEN) Could Be Positioned for a Surge?  Zacks.com
Agenus Coverage Initiated by Analysts at HC Wainright (AGEN)  Dakota Financial News